2085T Search Results


95
Cell Signaling Technology Inc egfr
Galectin‐3 regulated the <t>HER2/EGFR/PI3K/AKT</t> pathway. (a) Western blot analysis of AKT, PTEN, and EGFR (β‐actin as a loading control), p‐HER2, p‐AKT, p‐PI3K, <t>and</t> <t>p‐ERK1/2.</t> (b) qRT‐PCR analysis of EGFR , AKT , PTEN , and HER2 mRNA; ACTB mRNA was used as a loading control. (c) Immunofluorescence images of HER2 (red) and DAPI (blue). Scale bars, 100 μm. The significant differences are indicated by asterisk (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001)
Egfr, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/egfr/product/Cell Signaling Technology Inc
Average 95 stars, based on 1 article reviews
egfr - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier


N/A
Produced in rabbits immunized with E coli derived Human ILKAP fragment and purified by antigen affinity chromatography
  Buy from Supplier

N/A
Produced in rabbits immunized with E coli derived Human ILKAP fragment and purified by antigen affinity chromatography
  Buy from Supplier

Image Search Results


Galectin‐3 regulated the HER2/EGFR/PI3K/AKT pathway. (a) Western blot analysis of AKT, PTEN, and EGFR (β‐actin as a loading control), p‐HER2, p‐AKT, p‐PI3K, and p‐ERK1/2. (b) qRT‐PCR analysis of EGFR , AKT , PTEN , and HER2 mRNA; ACTB mRNA was used as a loading control. (c) Immunofluorescence images of HER2 (red) and DAPI (blue). Scale bars, 100 μm. The significant differences are indicated by asterisk (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001)

Journal: Thoracic Cancer

Article Title: Galectin‐3 enhances trastuzumab resistance by regulating cancer malignancy and stemness in HER2 ‐positive breast cancer cells

doi: 10.1111/1759-7714.14474

Figure Lengend Snippet: Galectin‐3 regulated the HER2/EGFR/PI3K/AKT pathway. (a) Western blot analysis of AKT, PTEN, and EGFR (β‐actin as a loading control), p‐HER2, p‐AKT, p‐PI3K, and p‐ERK1/2. (b) qRT‐PCR analysis of EGFR , AKT , PTEN , and HER2 mRNA; ACTB mRNA was used as a loading control. (c) Immunofluorescence images of HER2 (red) and DAPI (blue). Scale bars, 100 μm. The significant differences are indicated by asterisk (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001)

Article Snippet: The following primary antibodies were used in Western blot assays: galectin‐3 (ab76245), β‐actin (ab213262), CD44 (ab189524), CD24 (ab179821), CD133 (ab216323), Nanog (ab109250), E‐cadherin (ab231303), Notch1 (ab52627), HES1 (ab108937), PTEN (ab267787), HEY1 (ab154077) (Abcam); AKT (469 T1), phospho‐AKT (4060 T), PI3K (4257 T), phospho‐PI3K (4228 T), ERK1/2 (4695 T), phospho‐ERK1/2 (4370 T), HER2 (4290S), phospho‐HER2 (2243 T), EGFR (2085 T), and NICD1 (4147 T) (Cell Signaling Technology).

Techniques: Western Blot, Control, Quantitative RT-PCR, Immunofluorescence